C12Y 304/21034
Plasma kallikrein
Official title: Plasma kallikrein (3.4.21.34)
C12Y304/21034 (Plasma kallikrein) appears on 16 US grants and 42 published applications in this corpus.
Search patents in C12Y- Granted patents
- 16
- Published applications
- 42
- Assignees
- 23
- Inventors
- 115
- Latest grant
- 7 Apr 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 0 | 1 |
| 2004 | 0 | 2 |
| 2005 | 0 | 1 |
| 2006 | 0 | 0 |
| 2007 | 1 | 1 |
| 2008 | 0 | 0 |
| 2009 | 1 | 0 |
| 2010 | 0 | 1 |
| 2011 | 0 | 0 |
| 2012 | 1 | 0 |
| 2013 | 0 | 1 |
| 2014 | 0 | 2 |
| 2015 | 0 | 1 |
| 2016 | 1 | 1 |
| 2017 | 1 | 3 |
| 2018 | 1 | 1 |
| 2019 | 0 | 2 |
| 2020 | 1 | 2 |
| 2021 | 3 | 0 |
| 2022 | 1 | 5 |
| 2023 | 2 | 4 |
| 2024 | 1 | 4 |
| 2025 | 1 | 5 |
| 2026 | 1 | 5 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Modulation of prekallikrein (PKK) expression7 Apr 2026US 12,595,485 B2Ionis Pharmaceuticals, Inc.
- Assays for determining plasma kallikrein system biomarkers14 Oct 2025US 12,442,824 B2Takeda Pharmaceutical Company Limited
- Prekallikrein-modulating compositions and methods of use thereof23 Jul 2024US 12,042,509 B2ADARx Pharmaceuticals, Inc.
- Peptides inhibiting KLK1, KLK4, or KLK4 and KLK819 Dec 2023US 11,845,786 B2Daiichi Sankyo Company, Limited
- Modulation of prekallikrein (PKK) expression12 Dec 2023US 11,840,686 B2Ionis Pharmaceuticals, Inc.
- Methods for in vivo editing of klkb120 Aug 2026US 2026/0240959 A1Intellia Therapeutics, Inc.
- Compositions targeting klkb1 and methods of use thereof13 Aug 2026US 2026/0232843 A1Poseida Therapeutics, Inc.
- Anti-plasma kallikrein antibody dosing regimens for treating plasma kallikrein associated disorders16 Jul 2026US 2026/0201066 A1Astria Therapeutics, Inc.
- Compositions and Methods for Treating and Preventing Prekallikrein-Associated Conditions11 Jun 2026US 2026/0158051 A1Ionis Pharmaceuticals, Inc.
- Compositions and methods for genome editing4 Jun 2026US 2026/0151507 A1Demeetra Agbio, Inc.
Most cited
By later US patents
- Modulation of prekallikrein (PKK) expression15US 9,670,492 B2Ionis Pharmaceuticals, Inc. · 2017
- Kallikrein 7 modulators7US 8,309,596 B2Novartis AG · 2012
- Methods for modulating kallikrein (KLKB1) expression7US 9,315,811 B2Ionis Pharmaceuticals, Inc. · 2016
- Assays for determining plasma kallikrein system biomarkers6US 11,372,002 B2Takeda Pharmaceutical Company Limited · 2022
- Modulation of prekallikrein (PKK) expression5US 10,100,310 B2Ionis Pharmaceuticals, Inc. · 2018